Rezvilutamide

Rezvilutamide (SHR3680) is an orally active androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer[1][2].

Product Specifications

CAS Number

[1572045-62-5]

Product Name Alternative

SHR3680

UNSPSC

12352005

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rezvilutamide.html

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

S=C(N(C(C=C1)=CC=C1OC[C@@H](O)CO)C(C)2C)N(C(C=C3)=CC(C(F)(F)F)=C3C#N)C2=O

Molecular Formula

C22H20F3N3O4S

Molecular Weight

479.47

References & Citations

[1]SangjunYoo, et al. New drugs in prostate cancer. Prostate International Volume 4, Issue 2, June 2016, Pages 37-42.|[2]Veronica Mollica, et al. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells. 2019 Jan 11;8 (1) :43.|[3]Dai T, et al., A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients. Br J Clin Pharmacol. 2023 Feb;89 (2) :874-886.